Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
22,408
Recruiting, any sponsor type
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting22,408
- Not yet recruiting9,484
- Completed134,382
22,408 trials
Showing 1 to 25, recently updated first.
Haihua YuanAcademic, hospital or other
NCT07631871 · 10 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2029
Drug: Zanidatamab · For: Neoplasms; Solid Tumors; HER2 Positive Solid Tumor and 7 more
Sites: Shanghai, China
National Cancer Institute (NCI)NIH
NCT06149481 · 60 participants (planned) · Start Mar 26, 2024 · Primary completion Oct 31, 2027
Drug: Retifanlimab; Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform and 2 more · For: Metastatic Colorectal Cancer
Sites: Bethesda, Maryland
- Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASDPivotal-lookingRecruiting
Shanghai Auzone Biological Technology Co., Ltd.Industry
NCT06757504 · 150 participants (planned) · Start Jan 13, 2025 · Primary completion Jun 30, 2027
Drug: TTYP01 Tablets (12mg or 18mg); Placebo (Simulant TTYP01 Tablets) · For: Autism Spectrum Disorder (ASD)
Sites: Beijing, China; Changsha, China; Chengdu, China · 5 sites in all
Abhay Singh, MD MPHAcademic, hospital or other
NCT06630221 · 25 participants (planned) · Start Jun 17, 2025 · Primary completion Jan 1, 2028
Drug: Eltrombopag (EPAG) · For: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
Sites: Cleveland, Ohio
- Sleep Quality - Comparing the Effect of Ondansetron or Dexamethasone Given as Routine Prophylaxis Intraoperatively to Prevent Post Operative Nausea and Vomiting (SCORPION)Pivotal-lookingRecruiting
Telethon Kids InstituteAcademic, hospital or other
NCT07777276 · 500 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 17, 2029
Drug: Dexamethasone (IV); Ondansetron iv · For: Postoperative Sleep Quality; Postoperative Behaviour; Postoperative Recovery in Children and 3 more
Sites: Perth, Australia; São Paulo, Brazil · 3 sites in all
Stony Brook UniversityAcademic, hospital or other
NCT04814355 · 50 participants (planned) · Start Aug 1, 2018 · Primary completion Aug 31, 2028
Drug: Celecoxib 400 mg · For: Major Depressive Disorder; Neuroinflammation
Sites: Stony Brook, New York
Hangzhou Converd Co., Ltd.Industry
NCT07185243 · 24 participants (planned) · Start Jun 23, 2025 · Primary completion Jun 2027
Drug: recombinant human IL-21-expressing oncolytic vaccinia virus injection · For: Advanced Solid Tumors
Sites: Xiamen, China
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07391774 · 1,978 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 31, 2029
Drug: Anastrozole; Chemotherapy and 3 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8 and 2 more
Sites: Jonesboro, Arkansas; Auburn, California; Berkeley, California · 264 sites in all
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT06932068 · 77 participants (planned) · Start Mar 26, 2025 · Primary completion Oct 31, 2027
Drug: Iparomlimab and Tuvonralimab (QL1706); Oxaliplatin and 1 more · For: HER2 Negative; Low PD-L1 Expressing; Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Sites: Zhengzhou, China; Binzhou, China; Dezhou, China · 29 sites in all
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant AscitesPivotal-lookingRecruiting
Kyushu UniversityAcademic, hospital or other
NCT05438459 · 176 participants (planned) · Start Jun 8, 2022 · Primary completion Mar 31, 2032
Drug: GAIA-102; GAIA-102 and 6 more · For: Gastric Cancer; Pancreatic Cancer
Sites: Fukuoka, Japan
Virginia Commonwealth UniversityAcademic, hospital or other
NCT06185205 · 170 participants (planned) · Start Dec 12, 2023 · Primary completion Jan 31, 2031
Drug: Accelerated partial breast irradiation · For: Breast Cancer
Sites: Richmond, Virginia
Fortvita Biologics (USA)Inc.Industry
NCT07842393 · 32 participants (planned) · Start Oct 20, 2026 · Primary completion Mar 2, 2027
Drug: Investigational Drug: IBI3042; Matching Placebo · For: Healthy Volunteers (HV)
Sites: Lenexa, Kansas
AstraZenecaAstraZeneca (AZN)
NCT06103864 · 625 participants (planned) · Start Nov 23, 2023 · Primary completion Jul 28, 2027
Drug: Dato-DXd; Durvalumab and 5 more · For: Breast Cancer
Sites: Daphne, Alabama; Springdale, Arkansas; Duarte, California · 318 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT07723651 · 75 participants (planned) · Start Nov 30, 2026 · Primary completion May 31, 2032
Drug: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one · For: Metastatic Prostate Cancer; Prostate Cancer
Sites: St Louis, Missouri; Philadelphia, Pennsylvania; Houston, Texas
PfizerPfizer (PFE)
NCT07476287 · 40 participants (planned) · Start Jul 2, 2026 · Primary completion Mar 24, 2028
Drug: PF-08634404; Chemotherapy · For: Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer and 3 more
Sites: Duarte, California; Encinitas, California; Irvine, California · 75 sites in all
GenfitIndustry
NCT07694297 · 16 participants (planned) · Start Oct 16, 2026 · Primary completion Aug 2027
Drug: NTZ 500mg BID on top of SOC · For: Acute Decompensation of Liver Cirrhosis; Established Acute-on-Chronic Liver Failure
Sites: Kutaisi, Georgia; Tbilisi, Georgia · 6 sites in all
AusperBio Therapeutics Inc.Industry
NCT07370207 · 84 participants (planned) · Start Mar 6, 2026 · Primary completion Dec 31, 2028
Drug: AHB-137 · For: Hepatitis B, Chronic
Sites: Fitzroy, Australia; Hong Kong, China; Musashino, Japan · 9 sites in all
PfizerPfizer (PFE)
NCT07609914 · 400 participants (planned) · Start May 28, 2026 · Primary completion Jun 7, 2028
Drug: Rimegepant · For: Acute Treatment of Migraine
Sites: Canoga Park, California; Fresno, California; Los Angeles, California · 38 sites in all
National Cancer Institute (NCI)NIH
NCT05155033 · 78 participants (planned) · Start Aug 18, 2022 · Primary completion Sep 1, 2031
Drug: Pembrolizumab; Aldesleukin · For: Metastatic Melanoma; Advanced Locoregional Melanoma; Metastatic Renal Cell Carcinoma and 1 more
Sites: Bethesda, Maryland
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07388524 · 336 participants (planned) · Start Mar 2, 2027 · Primary completion Sep 30, 2032
Drug: Atezolizumab; Atezolizumab and Recombinant Human Hyaluronidase · For: Lung Non-Small Cell Carcinoma
Sites: Anaheim, California; Baldwin Park, California; Bellflower, California · 171 sites in all
- Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolPivotal-lookingRecruiting
Marea TherapeuticsIndustry
NCT07028749 · 316 participants (planned) · Start Jun 30, 2025 · Primary completion Nov 2027
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Anniston, Alabama; Mobile, Alabama; Little Rock, Arkansas · 62 sites in all
- Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruiting
Liu ShuAcademic, hospital or other
NCT07739485 · 30 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2027
Drug: Epirubicin and cyclophosphamide followed by paclitaxel oral solution · For: Triple -Negative Breast Cancer
Sites: Guiyang, China
Arvinas Inc.Industry
NCT06393738 · 329 participants (planned) · Start Sep 5, 2024 · Primary completion Dec 2028
Drug: ARV-393; Glofitamab · For: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Sites: New Haven, Connecticut; Miami, Florida; Detroit, Michigan · 28 sites in all
Sumitomo Pharma America, Inc.Industry
NCT06891885 · 12 participants (planned) · Start Apr 16, 2026 · Primary completion Oct 31, 2028
Drug: DSP-3077 Retinal Sheet Cohort 1; DSP-3077 Retinal Sheet Cohort 2 and 1 more · For: Retinitis Pigmentosa
Sites: Boston, Massachusetts; Minneapolis, Minnesota
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06498635 · 306 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 15, 2039
Drug: Durvalumab · For: Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 and 1 more
Sites: Jonesboro, Arkansas; Beverly Hills, California; Dublin, California · 287 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.